Review
Oct 2026
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.
If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.
J. Graff-Radford, Leah Karliner, Deborah E. Barnes et al.
· Lancet Neurology · 1 citation